<DOC>
	<DOCNO>NCT00286988</DOCNO>
	<brief_summary>The purpose study ass effectiveness , tolerability safety oral topiramate preventative management Cyclic Vomiting Syndrome . It believe topiramate decrease frequency , duration severity attack experience child adolescent Cyclic Vomiting Syndrome .</brief_summary>
	<brief_title>Topiramate Prophylactic Treatment Cyclic Vomiting Syndrome Children</brief_title>
	<detailed_description>There little control data preventative treatment Cyclic Vomiting Syndrome . The exist evidence consist small , retrospective clinical series evaluate symptomatic response five medication include cyproheptadine , propranolol , amitriptyline , phenobarbital pizotifen ( n &gt; 10 ) . These publish data consist uncontrolled retrospective report . In addition , vary inclusion criterion outcome ( i.e . obtain family recall ) use study limit basis upon compare relative effectiveness . During prospective baseline period , subject maintain cyclical vomiting record headache occurrence record characterize . ( Cyclical vomiting record maintain throughout study ) . The purpose study ass effectiveness , tolerability safety oral topiramate preventative management Cyclic Vomiting Syndrome use prospective design , establish diagnostic criterion ( ICHD 2004 ) , define , objective primary secondary endpoint .</detailed_description>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Topiramate</mesh_term>
	<criteria>Meet the2004 ICHD Criteria Cyclical Vomiting . 1 vomit attack last &gt; 24 hour duration 3 consecutive month 412 year age . If female , subject must : 1. premenarchal otherwise incapable pregnancy , 2. practice one follow method contraception least one month prior study entry : hormonal contraceptive , spermicide barrier , intrauterine device , partner sterility , 3. practicing abstinence agree continue abstinence use acceptable method contraception ( list ) sexual activity commence . Able take oral medication tablet form sprinkle form Subjects guardians must willing able : ) read comprehend write instruction , b ) complete assessment form , c ) return regular visit , ) adhere medication regimen . Subjects ( legally acceptable representative ) must sign informed consent document Exclusion Criteria Have take topiramate within 14 day prior start prospective baseline period . Have take certain medication cyclical vomit prophylaxis Have progressive neurological disorder structural disorder brain birth , trauma past infection . Subjects take medication migraine prophylaxis , within 2 week start prospective baseline period . Subjects start nonpharmacologic prophylactic approach ( e.g. , acupuncture , biofeedback , chiropractic method ) within 1 month prior Visit 1 . Require continue treatment anticonvulsant therapy nonmigraine condition . Significant major psychiatric disorder ( e.g. , major depression ) subject receive antipsychotic medication . History attempt suicide suicidal tendency . History substance abuse . Pregnant lactating female . Have clinically unstable neurological , cardiovascular , gastrointestinal , musculoskeletal , pulmonary disease . Have disease condition could compromise function body system could result altered absorption , excess accumulation , impaired metabolism excretion test medication ( e.g. , abnormal renal and/or hepatic function ) . Have active liver disease . Have receive investigational drug use investigational device within 30 day study entry . Employees investigator , study center , sponsor ( i.e. , principal investigator , subinvestigator ( ) , study coordinator , study staff , employee , contractor ) , direct involvement propose study study direction investigator , study center sponsor , well family member employee investigator .</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>April 2007</verification_date>
	<keyword>Preventative</keyword>
	<keyword>Open-Label</keyword>
	<keyword>Safety/Efficacy</keyword>
</DOC>